The Retinal Vein Occlusion drugs in development market research report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Retinal Vein Occlusion. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued products.
GlobalData tracks 41 drugs in development for Retinal Vein Occlusion by 34 companies/universities/institutes. The top development phase for Retinal Vein Occlusion is preclinical with 20 drugs in that stage. The Retinal Vein Occlusion pipeline has 41 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Retinal Vein Occlusion pipeline products market are: ANBITION, AffaMed Therapeutics US and F. Hoffmann-La Roche.
The key targets in the Retinal Vein Occlusion pipeline products market include Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, and Vascular Endothelial Growth Factor Receptor 2.
The key mechanisms of action in the Retinal Vein Occlusion pipeline product include Vascular Endothelial Growth Factor A Inhibitor with nine drugs in Phase III. The Retinal Vein Occlusion pipeline products include six routes of administration with the top ROA being Intravitreal and eight key molecule types in the Retinal Vein Occlusion pipeline products market including Small Molecule, and Monoclonal Antibody.
Retinal Vein Occlusion overview
Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age.
For a complete picture of Retinal Vein Occlusion’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
